| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f8c0982b0f02b1ed6d20a315370a3a3a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_26da3723d11a0786897640eceb4d464f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eb141b396e502bfce986c491d722e401 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55594
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7032
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-74
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1774
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N13-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-567
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-02 |
| filingDate |
2006-01-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2015-05-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d6fe264a9e6ae32b24615bdcf9d0f228
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c966bc854e2ac19acb9419278fa0df9e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4df4cad6092cfe8357f2f7fe992166d4 |
| publicationDate |
2015-05-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-2593715-C |
| titleOfInvention |
Bacterial glycolipid activation of cd1d-restricted nkt cells |
| abstract |
Disclosed are methods for activating an NKT cell, methods of stimulating an immune response in a subject, methods of improving vaccine efficacy, and methods of treating an infection. Also disclosed are methods of promoting tumor rejection, treating cancer, modulating autoimmunity and inhibiting allergen-induced hypersensitivity in subjects. The methods include contacting an NKT cell with a bacterial glycolipid complexed with a CD1 molecule to activate the NKT cell. The bacterial glycolipid may be derived from a member of the Class Alphaproteobacteria. |
| priorityDate |
2005-01-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |